BCAX Key Statistics, Chart & Performance
The current stock price of BCAX is 18.395 USD. In the past month the price increased by 8.78%. In the past year, price increased by 0.06%.
BCAX Latest News, Press Relases and Analysis
BCAX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.9 | 399.15B | ||
| AMGN | AMGEN INC | 15.1 | 177.80B | ||
| GILD | GILEAD SCIENCES INC | 15.13 | 153.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.36 | 116.09B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.3 | 81.82B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 804.98 | 54.24B | ||
| INSM | INSMED INC | N/A | 38.00B | ||
| NTRA | NATERA INC | N/A | 32.52B | ||
| BIIB | BIOGEN INC | 10.5 | 25.78B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.54 | 22.21B | ||
| INCY | INCYTE CORP | 15.52 | 19.57B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.30B |
Related stock screener links
About BCAX
Company Profile
Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company is headquartered in Boston, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2024-09-13. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
Company Info
BICARA THERAPEUTICS INC
116 Huntington Avenue Suite 703
Boston MASSACHUSETTS US
Employees: 55
Phone: 16174684219
BICARA THERAPEUTICS INC / BCAX FAQ
What does BICARA THERAPEUTICS INC do?
Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company is headquartered in Boston, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2024-09-13. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
What is the current price of BCAX stock?
The current stock price of BCAX is 18.395 USD. The price increased by 4.52% in the last trading session.
Does BICARA THERAPEUTICS INC pay dividends?
BCAX does not pay a dividend.
What is the ChartMill technical and fundamental rating of BCAX stock?
BCAX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy BCAX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BCAX.
What is the Short Interest ratio of BICARA THERAPEUTICS INC (BCAX) stock?
The outstanding short interest for BICARA THERAPEUTICS INC (BCAX) is 16.97% of its float.
BCAX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to BCAX. When comparing the yearly performance of all stocks, BCAX is one of the better performing stocks in the market, outperforming 89.89% of all stocks.
BCAX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BCAX. While BCAX has a great health rating, there are worries on its profitability.
BCAX Financial Highlights
Over the last trailing twelve months BCAX reported a non-GAAP Earnings per Share(EPS) of -2.24. The EPS decreased by -302.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.61% | ||
| ROE | -30.17% | ||
| Debt/Equity | 0 |
BCAX Forecast & Estimates
15 analysts have analysed BCAX and the average price target is 33.22 USD. This implies a price increase of 80.61% is expected in the next year compared to the current price of 18.395.